SAN FRANCISCO, CA, Nov. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a quarterly conference call to discuss its third quarter 2023 financial results on Monday, November 13th at 4:30 pm ET / 1:30 pm PT. The third quarter 2023 financial results press release will be issued at the market close on Monday, November 13th.
Teleconference Date/Time
Monday, November 13th at 4:30 pm ET / 1:30 pm PT
Teleconference and Webcast Information
To participate, please call 1 (844) 413-3972 at least 10 minutes prior to the start of the call and ask to join the American Shared Hospital Services call.
A simultaneous webcast of the call may be accessed through the Company's website, www.ashs.com, or at www.streetevents.com for institutional investors.
A replay of the call will be available at 1 (877) 344-7529, access code 1277407, through November 20, 2023. The call will also be available for replay on the Company’s website, www.ashs.com, for one year.
About American Shared Hospital Services (NYSE American: AMS)
American Shared Hospital Services (ASHS) is a leading provider of creative financial and turnkey solutions to Cancer Treatment Centers, hospitals, and large cancer networks worldwide. The company works closely with all major global Original Equipment Manufacturers (OEMs) that provide leading edge clinical treatment systems and software to treat cancer using Radiation Therapy and Radiosurgery. The company is vendor agnostic and provides financial support for a wide range of products including MR Guided Radiation Therapy Linacs, Advanced Digital Linear Accelerators, Proton Beam Therapy Systems, Brachytherapy systems and suites, and through the Company’s subsidiary, GK Financing LLC., the Leksell Gamma Knife product and services. For more information, please visit: www.ashs.com
Contacts:
American Shared Hospital Services
Ray Stachowiak
Executive Chairman
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations
PCG Advisory
Stephanie Prince
(646) 863-6341
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$3.40 |
| Daily Volume: | 13,783 |
| Market Cap: | US$21.520M |
November 20, 2023 September 14, 2023 September 06, 2023 August 24, 2023 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
